MX362363B - Uso de d-fagomina como agente inmunoestimulante del sistema inmunitario innato a nivel mucoso y para el control de procesos inflamatorios relacionados con una sobreactivacion de la respuesta inmunitaria humoral. - Google Patents

Uso de d-fagomina como agente inmunoestimulante del sistema inmunitario innato a nivel mucoso y para el control de procesos inflamatorios relacionados con una sobreactivacion de la respuesta inmunitaria humoral.

Info

Publication number
MX362363B
MX362363B MX2015010631A MX2015010631A MX362363B MX 362363 B MX362363 B MX 362363B MX 2015010631 A MX2015010631 A MX 2015010631A MX 2015010631 A MX2015010631 A MX 2015010631A MX 362363 B MX362363 B MX 362363B
Authority
MX
Mexico
Prior art keywords
immune response
fagomine
overactivation
inflammatory processes
humoral immune
Prior art date
Application number
MX2015010631A
Other languages
English (en)
Other versions
MX2015010631A (es
Inventor
Pumarola Segura Sergio
Maté Maria Carmen Antolin
Pagés Marta Llopis
Torras Maria De Los Angeles Calvo
Original Assignee
Pumarola Segura Sergio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pumarola Segura Sergio filed Critical Pumarola Segura Sergio
Publication of MX2015010631A publication Critical patent/MX2015010631A/es
Publication of MX362363B publication Critical patent/MX362363B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención pertenece al campo de productos nutricéuticos o agentes funcionales con capacidad inmunoestimulante para desencadenar mecanismos de la respuesta inmunitaria innata a nivel mucoso. Más específicamente, se refiere al uso del compuesto D-fagomina como agente inmunoestimulante de la respuesta inmunitaria innata en la mucosa y para la prevención o profilaxis de procesos inflamatorios o enfermedades asociados con una sobreactivación de la respuesta inmunitaria humoral. La invención también se refiere a una composición que comprende D-fagomina para la aplicación a la que se hace referencia anteriormente.
MX2015010631A 2013-02-18 2014-02-13 Uso de d-fagomina como agente inmunoestimulante del sistema inmunitario innato a nivel mucoso y para el control de procesos inflamatorios relacionados con una sobreactivacion de la respuesta inmunitaria humoral. MX362363B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13155586.4A EP2767284A1 (en) 2013-02-18 2013-02-18 D-Fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response
PCT/EP2014/052802 WO2014125013A1 (en) 2013-02-18 2014-02-13 D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response

Publications (2)

Publication Number Publication Date
MX2015010631A MX2015010631A (es) 2016-05-26
MX362363B true MX362363B (es) 2019-01-11

Family

ID=47739125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010631A MX362363B (es) 2013-02-18 2014-02-13 Uso de d-fagomina como agente inmunoestimulante del sistema inmunitario innato a nivel mucoso y para el control de procesos inflamatorios relacionados con una sobreactivacion de la respuesta inmunitaria humoral.

Country Status (12)

Country Link
US (1) US10233206B2 (es)
EP (2) EP2767284A1 (es)
CN (1) CN105246479B (es)
DK (1) DK2956136T3 (es)
EA (1) EA030688B1 (es)
ES (1) ES2711136T3 (es)
LT (1) LT2956136T (es)
MX (1) MX362363B (es)
PL (1) PL2956136T3 (es)
PT (1) PT2956136T (es)
UA (1) UA119746C2 (es)
WO (1) WO2014125013A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6808082B1 (ja) * 2019-12-27 2021-01-06 サントリーホールディングス株式会社 苦味が強化された緑茶飲料
CN112385539A (zh) * 2020-11-05 2021-02-23 贵州师范大学 一种果壳不破裂早熟优质黑米荞的选育方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006223285A (ja) * 2005-02-16 2006-08-31 Manjiro Kuwashige そば湯飲料とその加工方法
CN1321588C (zh) * 2005-03-22 2007-06-20 上海应用技术学院 荞麦谷果蔬泡腾片的制备方法
CN101129476B (zh) * 2006-08-21 2013-07-24 中国医学科学院药物研究所 桑枝生物碱有效部位在制备降血糖药物中的应用
CN101606936B (zh) * 2008-06-20 2011-12-28 中南大学 一种治疗糖尿病的药物组合物
WO2010029313A1 (en) * 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
CN101810276A (zh) * 2009-10-19 2010-08-25 郑鉴忠 荞麦萌芽活性食品生产方法
PL2549994T3 (pl) * 2010-03-25 2016-06-30 Taihua Shouyue Hong Kong International Co Ltd Zastosowanie D-fagominy jako inhibitora przylegania bakterii do komórek nabłonka
EP2593557A1 (en) * 2010-07-16 2013-05-22 Bioglane, S.L.N.E. A buckwheat extract enriched in d-fagomine

Also Published As

Publication number Publication date
CN105246479A (zh) 2016-01-13
EA201591518A1 (ru) 2016-01-29
PT2956136T (pt) 2019-02-19
CN105246479B (zh) 2019-03-15
EP2767284A1 (en) 2014-08-20
US10233206B2 (en) 2019-03-19
ES2711136T3 (es) 2019-04-30
US20150368283A1 (en) 2015-12-24
MX2015010631A (es) 2016-05-26
PL2956136T3 (pl) 2019-06-28
EP2956136B1 (en) 2018-11-21
WO2014125013A1 (en) 2014-08-21
DK2956136T3 (en) 2019-03-18
EA030688B1 (ru) 2018-09-28
UA119746C2 (uk) 2019-08-12
EP2956136A1 (en) 2015-12-23
LT2956136T (lt) 2019-03-12

Similar Documents

Publication Publication Date Title
IL267743B (en) Mutant isocitrate dehydrogenase inhibitor compounds, preparations containing them and their uses
IL289016A (en) Methods and medical preparation for the treatment and prevention of cardiomyopathy resulting from energy failure
EP3049070A4 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
PL3082831T3 (pl) Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL
PT3027738T (pt) Mscs no tratamento de doenças pulmonares inflamatórias
IL283432A (en) Preparations, methods and systems for the treatment of skin disorders
EP2872151A4 (en) ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
MX2015008766A (es) Compuestos cbd fluorados, composiciones y usos de los mismos.
IL244317A0 (en) Cortistatin analogs for the treatment of inflammatory and/or immune diseases
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EP2990419A4 (en) Preventive or therapeutic agent for inflammatory disease
IN2013MU03373A (es)
LT3021873T (lt) Kompozicija, skirta uždegiminių sąnarių ligų gydymui
MX2015010631A (es) Uso de d-fagomina como agente inmunoestimulante del sistema inmunitario innato a nivel mucoso y para el control de procesos inflamatorios relacionados con una sobreactivacion de la respuesta inmunitaria humoral.
GB2527233A (en) Composition comprising hydrocortisone
HK1208149A1 (en) Use of patchouli extract in the preparation of compositions with an anti-microorganism effect
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
HK1198128A1 (en) Use of arctigenin in the preparation of medicament for the treatment of gastrointestinal ulcer diseases
EP2958570A4 (en) THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PERIANAL DISORDERS
EP2999481A4 (en) Compositions and methods for diagnosing, preventing, and treating salmonella typhi and salmonella paratyphi infection
IN2013MU02732A (es)
GB201314015D0 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
UA86158U (en) Antibacterial agent
UA88100U (ru) Применение экстракта из листьев мать-и-мачехи (tussilago farfara l.) как противоязвенного средства

Legal Events

Date Code Title Description
FG Grant or registration